Data on the association of serum glypican-4 with future major adverse cardiovascular events and mortality in patients undergoing coronary angiography
Description
The present study included 760 patients who were referred to elective coronary angiography. Data were recorded by standardized interviews and by standardized examination protocols at our institution and were extracted from medical records. Serum GPC4 levels were measured with a commercially available ELSIA kit. During a follow up period the incidence of MACE, vascular mortality, and all-cause mortality were recorded. The Table includes baseline characteristics and GPC4 values as well as the endpoints major adverse cardiovascular events, vascular mortality, and all-cause mortality occurred during the follow-up period. GPC4 is given as ng/ml as well as z-transformed variable. Furthermore, GPC4 was categorized according to the optimal predictive cut-off value for GPC4. “Sex” describes the biological sex of subjects, whereas “0” stands for “male” and “1” for “female” patients. For other categorical variables“0” encodes “no” and “1” stands for “yes”.